Navigation Links
FDA: New Drug for Advance Kidney Cancer

The U.S. Food and Drug Administration (FDA) today approved Torisel (temsirolimus) for the treatment of a certain type of advanced kidney cancer known as renal cell carcinoma. Torisel was approved based on a study that showed use of the drug prolonged survival of patients with renal cell carcinoma. The drug is an enzyme inhibitor, a protein that regulates cell production, cell growth and cell survival.

'We have made significant advances in the battle against kidney cancer,' said Steven Galson, M.D., M.P.H., director of the FDAs Center for Drug Evaluation and Research. 'Torisel is the third drug approved for this indication in the past 18 months, and one that shows an increased time in survival for some patients.'

The approval of Torisel follows the December 2005 approval of Nexavar (sorafenib), which was based on a delay in progression of disease. In January 2006, Sutent (sunitinib) received accelerated approval based on durable response rate, or tumor size reduction, and was later demonstrated to delay tumor progression.

The safety and effectiveness of Torisel were shown in a clinical trial of 626 patients divided into three groups. One group received Torisel alone, another received a comparison drug called Interferon alfa, and a third received a combination of Torisel and interferon.

The group of patients who received Torisel alone showed a significant improvement in overall survival. The median overall survival was 10.9 months for patients on Torisel alone versus 7.3 months for those treated with the interferon alone. Progression-free survival (when the disease does not get worse) increased from 3.1 months on the interferon alone arm to 5.5 months on the Torisel alone arm. The combination of Torisel and interferon did not result in a significant increase in overall survival when compared with interferon alone.

The most common adverse reactions, occurring in at least 30 percent of Torisel-treate
'"/>




Page: 1 2

Related medicine news :

1. Advances in Treatment of Cataracts
2. Advanced STD programs required
3. Hope For Patients With Advanced Breast Cancer
4. Advances In Stem Cells Research
5. Breast Cancer Advance
6. Canadian Lung Cancer Study Lauded As Major Advance in Cancer Fight
7. Speedier Access To Advances In Breast Cancer Sought For Patients
8. HIV Vaccine Field Trials In Advanced Stage
9. Advance Funeral For AIDS-infected South African
10. New Screening Techniques to Lead Advances In Pain Therapy
11. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA New Drug for Advance Kidney Cancer

(Date:11/21/2008)...utious about future antibiotic resistance from wid...hDay News) -- People with moderate to severe chron...e to reduce the frequency of exacerbations through... report says. , The study, published in the fi... Respiratory and Critical Care Medicine , found th...
(Date:11/21/2008)...Newswire/ -- NursingCenter.com, the premier site,...eviewed content, has been,updated to improve the ...,users. Powered by Lippincott Williams & Wilki... peer-reviewed continuing education activities and... leading nursing journals.,Lippincott Williams &a...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc...ders overwhelmingly approved the proposals submitt...Teva Pharmaceuticals Industries Ltd. (Nasdaq: TE...verwhelming support of the transaction by the Barr...man and CEO. "We are pleased with the progress tha...
(Date:11/21/2008)...swire/ -- For the second year in a row and the t...are Worldwide,s agency network won more creative a...nual international RX Club Show. , , Nine ...otal of 59 RX Club Awards of Excellence, including...are Worldwide agencies include Caudex Medical, ech...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
...lier to develop a serious intestinal disorder if t...rythromycin, say US scientists. A research team f...g to pyloric stenosis, a condition that affects ab...e most common cause of abdominal surgery in infant...
...a strain of drug-resistant E. coli has emerged as ... E. coli is a normal inhabitant of the digestive t...nary infections. But while E. coli from bad food i...ve miseries, urinary tract infections were thought...
...independent pharmaceutical company in the United S...tological conditions. Based in Wilmington, Mass., ...ated to the specialty of pediatrics. Medicis Pharm... today announced that they have entered into a def...
...Medical School have looked at the use of complemen...eople. They find that the use of 20 therapies - fr...ty since the 1960s. A new survey reveals that comp...n popular, although the type of therapies used has...
Other Medicine News:
(Date:11/20/2008)...re-FirstCall/ -- Duska Therapeutics,Inc., (OTC B...submitted its,pivotal Phase 3 ATPace clinical tri...ssessment (SPA) procedure with the U.S. Food and D...uring an agreement with the FDA, Duska intends to ...cebo-controlled and randomized Phase 3,clinical t...
(Date:11/20/2008)...Newswire/ -- The Scandinavian-based drug,developm...of studies on its,lead antimicrobial candidate LT...studies showed that the novel lytic peptidomimetic...cantly better towards killing Staphylococcus,aure...tandard drugs. In,addition to this it has proven ...
(Date:11/19/2008)...ndings on critical enzyme,s regulation may hold ke... disorders , , MEMPHIS, Tenn., Nov. 19 /PRN...ldren,s Research Hospital have gained new insights...orses called calpains. , , As the cell,s m...cellular processes, including the movement of cell...
(Date:11/18/2008)...stCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a speci...pment Company,and Sosei Group Corporation ("Sose...onal biopharmaceutical company, today announce tha...e-clinical efficacy data for NSL-043/SD118.,This ...uropathic pain and has,successfully completed Pha...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Chindex International Announces Shelf Registration Related Strategy and Guidance 5368 1Chindex International Announces Shelf Registration Related Strategy and Guidance 5368 2Chindex International Announces Shelf Registration Related Strategy and Guidance 5368 3Chindex International Announces Shelf Registration Related Strategy and Guidance 5368 4Chindex International Announces Shelf Registration Related Strategy and Guidance 5368 5Girls young women can cut risk of early breast cancer through regular exercise 19246 1Girls young women can cut risk of early breast cancer through regular exercise 19246 2Blood Thinner No Help for Dialysis Treatment 19243 1Blood Thinner No Help for Dialysis Treatment 19243 2Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 19240 1Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 19240 2Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations 19240 3
The Self-Cath family of 100% latex-free catheters offers patients a variety of options for intermittent self-catheterization. Each catheter is made of flexible medical grade PVC and has smooth fire
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use.
An indirect immunofluorescence antibody test for the detection and semi-quantitation of anti-neutrophil cytoplasmic antibodies (ANCA) in human serum. ANCA are found in the sera of patients with necro
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex
Medicine Products: